YG 1699
Alternative Names: ABSK101; YG-1699Latest Information Update: 28 Feb 2026
At a glance
- Originator Youngene Therapeutics
- Class Antifibrotics; Antihyperglycaemics; Heart failure therapies; Small molecules
- Mechanism of Action Sodium-glucose transporter 1 inhibitors; Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Type 1 diabetes mellitus
- Preclinical Cystic fibrosis
- No development reported Diabetes mellitus; Diabetic nephropathies; Heart failure
Most Recent Events
- 28 Feb 2026 No recent reports of development identified for phase-I development in Diabetic-nephropathies in China (PO)
- 28 Feb 2026 No recent reports of development identified for phase-I development in Heart-failure in China (PO)
- 28 Feb 2025 No recent reports of development identified for phase-I development in Diabetes-mellitus(In volunteers) in China (PO)